Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

OptiBiotix rises as its signs a production and commercialisation agreement

The agreement will allow Fine Foods to promote specific formulations and presentations containing the OptiBiotix's LPLDL strain to customers seeking to reduce cholesterol, blood pressure and cardiovascular risk
Heart symbol
LPLDL is a viable non-prescription alternative to cholesterol-lowering statins

Shares in OptiBiotix Health plc (LON:OPTI) surged after the human microbiome specialist announced a production and commercialisation agreement with Fine Foods & Pharmaceuticals.

The agreement grants Fine Foods an exclusive licence for the production and supply of five formulations containing OptiBiotix's LPLDL strain in Europe in return for royalty payments and a commitment to maximising the financial return for both parties.

READ: OptiBiotix Health now able to pay dividends following capital reorganisation

LPLDL works by affecting the metabolism of bile acids in the intestine and is a viable non-prescription alternative to cholesterol-lowering statins, which are known to have unwanted side effects for many users.

Fine Foods is based in Italy and has more than 30 years' experience in the design, development and manufacture of customised formulations and presentations for the pharmaceutical and food supplement industry.

It has full good manufacturing practice-certified production facilities and a recognised expertise in developing unique formulations and presentations containing probiotic strains.

Under the terms of the agreement, Fine Foods has an exclusive licence to produce and commercialise five new formulations containing OptiBiotix's LPLDL: one for glucose control; one for reduction of high blood pressure; one for reduction of cholesterol levels and two for the reduction of cardiovascular risk.

These proprietary formulations will be marketed in innovative presentations including sachets and 'melt in the mouth' sticks, to Fine Foods’ extensive European network in both the pharmaceutical and food supplement industry.

“This agreement extends the range of products and presentations containing OptiBiotix's LPLDL and creates an opportunity to access global pharmaceutical markets with an established industry supplier,” said Stephen O’Hara, the chief executive officer of OptiBiotix.

“We chose Fine Foods due to its industry experience, reputation, rapid revenue growth, and impressive client list of global customers in both the pharmaceutical and food supplement sectors. We believe our strategy of identifying and building partnerships with industry-leading partners like Fine Foods, provides the best opportunity of rapidly building revenue streams, and establishing LPLDL as a leading global brand," he added.

House broker finnCap said it was encouraged by the announcement, which continues to demonstrate the company’s ability to attract high calibre, global partners, and eager to use the potential inherent within LPLDL.

“We expect further announcements for regions in which OPTI products can help differentiate and expand existing marketing products,” the broker said.

Shares in OptiBiotix were up 4.7% at 62.8p in early deals. 

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use